Ocugen Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Ocugen Inc in the market include companies like Pfizer Inc, Moderna Inc, Johnson & Johnson, and Novavax Inc.

Ocugen Inc is a pharmaceutical company with a strong focus on developing and commercializing gene therapies to treat blindness diseases. Established in 2013, Ocugen has been dedicated to advancing innovative treatments for various ocular disorders. The company's proprietary modifier gene therapy platform has shown promising results in preclinical and early clinical trials. Ocugen also partners with biopharmaceutical companies to expedite the development and distribution of potential therapies. With a commitment to improving patients' vision and quality of life, Ocugen Inc continues to make strides in the field of ophthalmology research and development.

Ocugen Inc has achieved several significant milestones in its history. The company successfully secured a strategic collaboration with Bharat Biotech to co-develop COVAXIN, a potential COVID-19 vaccine, for the US market. Ocugen also submitted a Emergency Use Authorization (EUA) application to the US FDA for COVAXIN, which marks a major milestone in bringing a potential vaccine to the market. Additionally, Ocugen received orphan drug designation from the FDA for its gene therapy product candidate for the treatment of RHO mutation-associated retinal degenerative disease. These milestones demonstrate Ocugen's dedication to advancing innovative healthcare solutions and its potential for growth in the biopharmaceutical industry.

Ocugen Inc is primarily present in the United States, focusing on the development and commercialization of innovative gene therapies. The company's headquarters are located in Malvern, Pennsylvania. Ocugen Inc also has a strong presence in India, where it has a subsidiary called Ocugen India Pvt. Ltd. Through partnerships and collaborations, Ocugen Inc strives to expand its reach globally, with a mission to provide solutions for rare and underserved diseases worldwide.

Ocugen Inc represents values of innovation, collaboration, and excellence in the biopharmaceutical industry. The company is dedicated to addressing unmet medical needs and improving patient outcomes through the development and commercialization of novel therapies. Ocugen Inc is committed to prioritizing patients and ensuring the highest standards of quality and safety in their products. With a focus on research and development, the company strives to bring breakthrough treatments to market, aiming to transform the lives of patients worldwide. Ocugen Inc's corporate philosophy centers around a patient-centric approach, ethical conduct, and delivering value to shareholders.

Analysts currently set an average price target of 10,20 USD for the Ocugen stock (median: 9,18 USD), implying +655,6 % versus the latest price. The consensus is based on 11 analyst ratings.

Ocugen Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Ocugen stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Ocugen to generate revenue of 4,74 M USD and earnings per share of −0,28 USD.

Ocugen Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Ocugen share trades at 1,17 EUR (1,35 USD).

The Ocugen share (OCGN) is listed on 5 stock exchanges, including: NASDAQ (OCGN), Frankfurt (2H51.F), München (2H51.MU), Düsseldorf (2H51.DU), Hamburg (2H51.HM).

Ocugen Inc is a biopharmaceutical company based in the USA that focuses on the development and commercialization of innovative therapeutics for eye diseases. Ocugen's business model is based on partnerships with leading companies in the pharmaceutical industry as well as the development of its own products. The company operates in various areas including the development of therapeutics for eye diseases, licensing of technologies, products, and patents, and conducting clinical trials. Ocugen offers a variety of products, such as OCU300 for glaucoma patients and OCU200 for patients with dry eye disease. The company also has other products in the pipeline, such as OCU400 for retinal degeneration and OCU450 for retinal pigment degeneration. Ocugen's business model is focused on the development and commercialization of innovative therapeutics for eye diseases through partnerships and the development of its own products. By continuously evolving and expanding its offerings, Ocugen is well-positioned to meet the increasing demand for effective therapeutics for eye diseases in the future.

odotettu liikevaihto Ocugen on 4,74 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Ocugen on −88,53 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Ocugen:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,76. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Ocugen-osakkeen arvostusta.

Ocugen:n hinta-myynti-suhde (P/S) on tällä hetkellä 88,96. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Ocugen-osakkeen arvostuskennuslukuna.

Ocugen:n Eulpool-laatuscore on 3/10.

Ocugen:n ISIN on US67577C1053. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Ocugen:n WKN on A2PSZH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Ocugen:n ticker on OCGN. Tämä pörssinoteeraus käytetään Ocugen-osakkeiden kauppaan pörssissä.

Ocugen maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Ocugen kuuluu sektoriin 'Terveydenhuolto'.

Ocugen:n osingot jaetaan valuutassa USD.